Abstract
Background: Management of musculoskeletal tumors remains challenging for orthopedic surgeons. The aim of this cross-sectional study was to present the prevalence and localization of musculoskeletal disorders diagnosed and treated at a tertiary referral military hospital.
Method: A total of 552 patients' medical records who presented to our clinic between 2009 and 2014 with the diagnosis of musculoskeletal tumors were retrospectively analyzed according to age, gender, bone/soft tissue localization, histopathological diagnosis, incidence, and treatment.
Results: Of the cases diagnosed with tumor, 225 were soft tissue localized, 317 bone localized, and 10 tumor-like lesions. The most common primary benign soft tissue tumors were lipoma, ganglion, and giant cell tumor of tendon sheath, while the most common malignant soft tissue tumors were liposarcoma and synovial sarcoma, respectively. The most common primary bone tumors were osteochondroma, enchondroma, and simple bone cyst, while the most common malignant bone tumors were osteosarcoma, Ewing sarcoma and chondrosarcoma, respectively. Myositis ossificans was found as the most common tumor-like lesion.
Conclusion: Descriptive data in musculoskeletal tumors is crucial in terms of improving treatment and reducing mortality. In this study, no significant difference was found between the data of tertiary military hospital regarding epidemiology of musculoskeletal system tumors and those from the literatures around Turkey.
Introduction
Although musculoskeletal tumors including bone and soft tissue tumors are relatively rare pathologies among total world cancer incidence, the management should compromise great attention (1). While great interest in orthopedic oncology as a subspecialty has been expanding in many countries, it remains challenging in orthopedic practice due to ignored educational opportunities (2).
More than 80% of the population of the world is located in developing countries where considerable diversity in terms of resource and expertise availability still exists in managing musculoskeletal tumors (3). Furthermore, a large number of patients in these countries are treated by inexperienced surgeons who have little knowledge and update about musculoskeletal oncology principles (4, 5).
In Turkey, there are few centers dealing with the management of orthopedic oncology. Among those centers, tertiary military hospital, is primarily responsible for the management of musculoskeletal tumors in military personnel and their families. Lack of subspecialized centers in military health system organization chart, the patients with a diagnosis of whether bone or soft tissue tumors in all around the country is referred to the tertiary military hospital.
In this report, we aimed to present 5-year data and experience of tertiary military hospital on musculoskeletal oncology among the military personnel's and their families. In addition, it is emphasized that the mission of our hospital is not only the war-related injury management, but also the musculoskeletal tumor treatment and prevention of labor loss.
Materials and Methods
A total of 552 bone and soft tissue tumors of 552 consecutive patients who underwent musculoskeletal oncologic surgery between 2009 and 2014 were retrospectively analyzed. A written informed consent was obtained from each patient. The study protocol was approved by Gülhane Military Medical Academy Local Ethics Committee (2014-13). The study was conducted in accordance with the principles of the Declaration of Helsinki.
All patients age, gender, diagnosis, tumor localization, and treatment were analyzed. All tumoral pathologies were divided as bone, soft tissue, and tumor-like lesions, and classified in separate groups regarding upper and lower extremities with the status of benign, malignant and tumor-like lesions (Tables 1–10).
Table 1
| Soft Tissue | Bone | Tumor like lesions | Total | |||
|---|---|---|---|---|---|---|
| Benign | Malignant | Benign | Malignant | |||
| Upper extremity | 102 | 8 | 64 | 14 | 2 | 190 |
| Male | 70 | 6 | 53 | 8 | 2 | 139 |
| Female | 32 | 2 | 11 | 6 | 0 | 51 |
| Lower extremity | 89 | 26 | 195 | 44 | 8 | 362 |
| Male | 65 | 20 | 177 | 34 | 7 | 303 |
| Female | 24 | 6 | 18 | 10 | 1 | 59 |
| Total | 191 | 34 | 259 | 58 | 10 | 552 |
| Male | 135 | 26 | 230 | 42 | 9 | 442 |
| Female | 56 | 8 | 29 | 16 | 1 | 110 |
Distribution of tumors in the extremity.
Table 2
| Diagnosis | N (n = 102) | Age (Year) – (Min-Max/Median) | Location | Treatment | Recurrence | Revision |
|---|---|---|---|---|---|---|
| Hemangioma | 3 | 19–43/21 | Arm | 2 Excision 1 Follow-up | – | – |
| Giant cell tumor of the tendon sheath | 37 | 18–45/23 | 30 Hand 7 Wrist | Excision | 7 | Excision |
| Lipoma | 6 | 21–41/29 | 4 Shoulder 1 Arm 1 Forearm | Excision | - | - |
| Synovial chondromatosis | 1 | 25 | Shoulder | Excision | – | – |
| Aggressive fibromatosis (Desmoid tumor) | 2 | 14–24 | 1 Shoulder 1 Forearm | Excision | – | – |
| Fibroma | 1 | 20 | Wrist | Excision | – | – |
| Ganglion | 52 | 18–59/26 | 33 Arm 19 Wrist | Excision | 3 | Excision |
Benign soft tissue tumors of the upper extremity.
Table 3
| Diagnosis | N (n = 8) | Age (Year) – (Min-Max/Median) | Location | Treatment | Recurrence | Revision |
|---|---|---|---|---|---|---|
| Synovial Sarcoma | 1 | 22 | Wrist | Below-elbow amputation | – | – |
| Dermatofibrosarcoma Protuberans | 1 | 23 | Arm | Wide excision | – | – |
| Rhabdomyosarcoma | 1 | 19 | Elbow (Antecubital) | Above-elbow amputation | – | – |
| Liposarcoma | 5 | 45–59/52 | 2 Shoulder 2 Arm 1 Forearm | Wide excision | 3 | 2 Wide excision 1 Above-elbow amputation |
Malignant soft tissue tumors of the upper extremity.
Table 4
| Diagnosis | N (n = 64) | Age (Year) – (Min-Max/Median) | Location | Treatment | Recurrence | Revision |
|---|---|---|---|---|---|---|
| Chondroblastoma | 2 | 24–25 | 1 Humerus 1 Radius | Curettage + grafting | – | – |
| Enchondroma | 16 | 11–43/21 | Hand | Curettage + grafting | – | – |
| Osteochondroma | 7 | 5–22/20 | 3 Scapula 2 Humerus 2 Hand | 6 Excision 1 Follow-up | – | – |
| Aneurysmal bone cyst | 7 | 8–37/19 | 3 Humerus 2 Radius 1 Ulna 1 Scapula | 3 Curettage + grafting 2 Curettage + grafting + prophylactic fixation 2 Curettage + cementation | 1 | Curettage + cementation |
| Osteoblastoma | 2 | 20–32 | Humerus | Curettage + cementation | – | – |
| Simple bone cyst | 9 | 6–36/21 | 8 Humerus 1 Ulna | 8 Curettage + grafting 1 Curettage + grafting + prophylactic fixation | – | – |
| Osteoid osteoma | 8 | 11–41/21 | 4 Humerus 2 Hand 2 Scapula | Percutaneous curettage | – | – |
| Fibroxanthoma | 1 | 22 | Hand | Follow-up | – | – |
| Giant cell tumor of bone | 3 | 21–25/22 | 2 Radius 1 Ulna | 2 Curettage + cementation 1 Resection + biological reconstruction + fixation | 1 | Curettage + cementation |
| Fibrous dysplasia | 7 | 19–25/21 | 7 Humerus | 4 Curettage + grafting + prophylactic fixation 3 Curettage + grafting | – | – |
| Chondromyxoid fibroma | 2 | 20–29 | Humerus | 1 Curettage + grafting + prophylactic fixation 1 Curettage + grafting | – | – |
Benign bone tumors of the upper extremity.
Table 5
| Diagnosis | N (n = 14) | Age (Year) – (Min-Max/Median) | Location | Treatment | Recurrence | Revision |
|---|---|---|---|---|---|---|
| Ewing sarcoma | 5 | 10–28/21 | 3 Humerus 1 Clavicula 1 Scapula | 3 Biological reconstruction 2 Tumor resection prosthesis | – | – |
| Osteosarcoma | 3 | 21–24/22 | 1 Humerus 1 Radius 1 Ulna | 2 Biological reconstruction 1 Tumor resection prosthesis | 1 | Shoulder disarticulation |
| Chondrosarcoma | 3 | 38–52/47 | Humerus | Tumor resection prosthesis | 1 | Forequarter amputation |
| Epithelioid sarcoma | 1 | 20 | Radius | Biological reconstruction | – | – |
| Metastasis | 2 | 55–77 | Humerus | Curettage + cementation + fixation | – | – |
Malignant bone tumors of the upper extremity.
Table 6
| Diagnosis | N (n = 89) | Age (Year) – (Min-Max/Median) | Location | Treatment | Recurrence | Revision |
|---|---|---|---|---|---|---|
| Synovial chondromatosis | 5 | 20–23/21 | 4 Knee 1 Ankle | Excision | – | – |
| Giant cell tumor of the tendon sheath | 8 | 21–45/25 | 4 Foot 3 Knee 1 Ankle | Excision | 1 | Excision |
| Hemangioma | 8 | 15–45/20 | 3 Popliteal fossa 2 Thigh 2 Foot 1 Knee | 5 Excision 3 Follow-up | – | – |
| Lipoma | 21 | 19–63/22 | 8 Thigh 5 Cruris 2 Popliteal fossa 3 Foot 2 Ankle 1 Hip | Excision | – | – |
| Ganglion | 27 | 21–52/36 | 15 Foot 3 Knee 3 Popliteal fossa 3 Cruris 3 Ankle | Excision | – | – |
| Morton neuroma | 12 | 23–37/27 | Foot | Excision | 1 | Excision |
| Schwannoma | 1 | 22 | Thigh | Excision | – | – |
| Epidermal cyst | 1 | 21 | Foot | Excision | – | – |
| Fibroma | 2 | 20–28 | Thigh | Excision | – | – |
| Pigmented villonodular synovitis | 3 | 17–38/20 | 2 Knee 1 Ankle | Excision | – | – |
| Aggressive fibromatosis (desmoid tumor) | 1 | 26 | Foot | Excision | – | – |
Benign soft tissue tumors of the lower extremity.
Table 7
| Diagnosis | N (n = 26) | Age (Year) – (Min-Max/Median) | Location | Treatment | Recurrence | Revision |
|---|---|---|---|---|---|---|
| Liposarcoma | 10 | 40–67/53 | 7 Thigh 1 Popliteal fossa 1 Cruris 1 Pelvis | 8 Wide excision 2 Above-knee amputation | 2 | 1 Wide excision 1 Above-knee amputation |
| Synovial Sarcoma | 9 | 20–45/24 | 1 Pelvis 4 Hip 2 Knee 1 Ankle 1 Foot | 3 Tumor resection prosthesis 3 Wide excision 1 Below-knee amputation 1 Hip disarticulation 1 Hemipelvectomy | 2 | 1 Above-knee amputation 1 Below-knee amputation |
| Clear cell sarcoma | 1 | 55 | Cruris | Wide excision | – | – |
| Kaposi sarcoma | 1 | 75 | Ankle | Below-knee amputation | – | – |
| Rhabdomyosarcoma | 1 | 6 | Thigh | Wide excision | – | – |
| Fibrosarcoma | 3 | 20–65/24 | 1 Hip 1 Thigh 1 Cruris | 2 Wide excision 1 Hip disarticulation | – | – |
| Adrenocortical carcinoma metastasis | 1 | 2 | Thigh | Wide excision | – | – |
Malignant soft tissue tumors of the lower extremity.
Table 8
| Diagnosis | N (n = 195) | Age (Year) – (Min-Max/Median) | Location | Treatment | Recurrence | Revision |
|---|---|---|---|---|---|---|
| Osteochondroma | 49 | 12–37/21 | 29 Femur 12 Tibia 1 Calcaneus 3 Metatarsal 2 Pelvis 2 Talus | 45 Excision 4 Follow-up | – | – |
| Fibrous dysplasia | 16 | 19–36/23 | 8 Femur 8 Tibia | 9 Curettage + grafting 4 Curettage + grafting + prophylactic fixation 3 Follow-up | – | – |
| Giant cell tumor of bone | 14 | 20–37/25 | 8 Femur 6 Tibia | 11 Curettage + cementation 3 Curettage + cementation + prophylactic fixation | 2 | Curettage + cementation |
| Aneurysmal bone cyst | 15 | 6–38/24 | 6 Femur 3 Pelvis 1 Patella 1 Tibia 1 Fibula 3 Calcaneus | 13 Curettage + grafting 2 Curettage + grafting + prophylactic fixation | 1 | Curettage + grafting |
| Osteoblastoma | 4 | 12–21/20 | 1 Femur 1 Tibia 1 Calcaneus 1 Talus | Curettage + grafting | – | – |
| Simple bone cyst | 23 | 19–38/28 | 9 Femur 2 Tibia 8 Calcaneus 1 Patella 1 Acetabulum 2 Talus | 18 Curettage + grafting 4 Curettage + grafting + prophylactic fixation 1 Follow-up | – | – |
| Osteoid osteoma | 39 | 14–38/22 | 19 Femur 17 Tibia 1 Fibula 1 Talus 1 Metatarsal | Percutaneous curettage | – | – |
| Enchondroma | 13 | 20–46/30 | 7 Femur 2 Tibia 1 Pelvis 1 Talus 2 Phalanx | 6 Curettage + grafting 1 Curettage + grafting + prophylactic fixation 6 Follow-up | – | – |
| Chondroblastoma | 7 | 19–34/21 | 3 Femur 3 Tibia 1 Talus | 6 Curettage + grafting 1 Curettage + cementation | – | – |
| Non-ossifying fibroma | 2 | 21–25 | Femur | 1 Curettage + grafting 1 Follow-up | – | – |
| Intraosseous lipoma | 5 | 21–31/27 | Calcaneus | Curettage + grafting | – | – |
| Fibrous cortical defect | 5 | 21–29/21 | 3 Femur 2 Tibia | 3 Follow-up 2 Curettage + grafting | – | – |
| Chondromyxoid fibroma | 1 | 23 | Femur | Curettage + grafting | – | – |
| Intraosseous hemangioma | 1 | 49 | Tibia | Curettage + grafting | – | – |
| Eosinophilic granuloma | 1 | 21 | Iliac wing | Curettage + grafting | – | – |
Benign bone tumors of the lower extremity.
Table 9
| Diagnosis | N (n = 44) | Age (Year) – (Min-Max/Median) | Location | Treatment | Recurrence | Revision |
|---|---|---|---|---|---|---|
| Osteosarcoma | 20 | 5–34/20 | 14 Femur 4 Tibia 2 Pelvis | 15 Tumor resection prosthesis 2 Biological reconstruction 2 Hemipelvectomy 1 Hip disarticulation | 3 | 2 Total femur tumor resection prosthesis 1 Above-knee amputation + 2 Arthrodesis (due to 1 osteomyelitis + 1 non-union) |
| Metastasis | 8 | 34–68/58 | 7 Femur 1 Humerus | 5 Curettage + cementation + fixation 2 Cemented partial hip prosthesis 1 Tumor resection prosthesis | – | – |
| Ewing sarcoma | 7 | 11–22/14 | 2 Iliac wing 2 Femur 1 Tibia 1 Fibula 1 Glenoid | 3 Biological reconstruction 3 Tumor resection prosthesis 1 Wide resection | – | – |
| Chondrosarcoma | 6 | 19–54/40 | 3 Pelvis 2 Femur 1 Acetabulum | 3 Tumor resection prosthesis 2 Biological reconstruction 1 Hemipelvectomy | 1 | Wide resection |
| Multiple myeloma + plasmacytoma | 2 | 30–85 | Femur | 1 Curettage + cementation 1 Cemented partial hip prosthesis | – | – |
| Fibrosarcoma | 1 | 22 | Iliac wing | Custom-made tumor resection prosthesis | – | – |
Malignant bone tumors of the lower extremity.
Table 10
| Diagnosis | N (n = 10) | Age (Year) – (Min-Max/Median) | Location | Treatment | Recurrence | Revision |
|---|---|---|---|---|---|---|
| Myositis ossificans | 7 | 19-52/22 | 1 Arm 1 Wrist 2 Hip 2 Thigh 1 Cruris | Excision | – | – |
| Brodie abscess | 2 | 21-46 | 1 Fibula 1 Tibia | Curettage | – | – |
| Cyst hydatid | 1 | 67 | Iliac wing | Excision + application of hypertonic solution | – | – |
Tumor like lesions.
Metastasis were considered as malignant tumors and classified in the tables of malignant tumors.
Biopsies of tumors were performed by two clinicians primarily responsible for the diagnosis of musculoskeletal tumors. No complications were encountered during or after procedures. When the diagnosis was malignant or metastasis, patients were consulted medical and radiation oncology departments whether they would receive neoadjuvant chemotherapy or radiotherapy to obtain smaller mass or prevent spreading. In need of neoadjuvant care, the definitive surgeries were scheduled after chemo/radiotherapies.
There is no difficulty in accessing chemotherapy drugs in our country where routine treatments were given by medical and radiological oncologist according to the diagnosis.
Statistical Analysis
Statistical analysis was performed using the IBM SPSS for Mac version 23.0 software (IBM Corporation, Armonk, NY). Descriptive data were expressed in minimum, maximum, median and number and frequency.
Results
Of the patients, 110 (20%) were female and 442 (80%) were male. Of the tumoral lesions 190 (34%) were localized in the upper extremity from shoulder joint to fingertip of hand, 362 (66%) in the lower extremity from pelvic region to fingertip of foot (Table 1).
Of all cases, 225 (191 benign, 34 malignant) were primary soft tissue tumors, 317 (259 benign, 58 malignant) were primary bone tumors, and 10 were tumor-like lesions (Table 1).
Of primary soft tissue tumors of benign nature, 102 (53%) were localized in upper extremities and 89 (47%) were localized in lower extremities including hemangioma, giant cell tumor of the tendon sheath, lipoma, synovial chondromatosis, desmoid tumor (aggressive fibromatosis), fibroma, pigmented villonodular synovitis, schwannoma, Morton neuroma, epidermal cyst, and ganglion (Tables 1, 2, 6), whereas 8 (24%) malignant soft tissue tumors were localized in upper extremity, and 26 (76%) were in lower extremity with the diagnosis of synovial sarcoma, dermatofibrosarcoma protuberans, rhabdomyosarcoma, clear cell sarcoma, Kaposi sarcoma, fibrosarcoma, adrenocortical carcinoma metastasis, and liposarcoma (Tables 1, 3, 7).
On the other hand, regarding benign primary bone tumors, 64 (25%) were localized in the upper extremity, and 195 (75%) were in the lower extremity including chondroblastoma, enchondroma, osteochondroma, aneurysmal bone cyst, osteoblastoma, simple bone cyst, osteoid osteoma, fibroxanthoma, giant cell tumor of bone, fibrous dysplasia, chondromyxoid fibroma, non-ossifying fibroma, intraosseous lipoma, fibrous cortical defect, intraosseous hemangioma, and eosinophilic granuloma (Tables 1, 4, 8). Furthermore, 14 (24%) malignant bone tumors were localized in the upper extremity, and 44 (76%) were in the lower extremity with a variety of Ewing sarcoma, osteosarcoma, chondrosarcoma, epithelioid sarcoma, multiple myeloma, solitary plasmacytoma, fibrosarcoma, and metastasis (Tables 1, 5, 9).
Of tumor-like lesions, 7 myositis ossificans, 2 Brodie abscess, and a bone cyst hydatid were managed without any recurrence (Table 10).
Regarding medical and radiation treatments, we observed chemotherapy resistance in some of Ewing sarcomas which were followed by autologous bone marrow transplantation sequentially. On the other hand, outcomes of conventional chemotherapy or radiotherapy in other tumors were successful in terms of controlling local recurrence or metastasis.
A detailed explanation regarding treatment options, recurrence, and revisions were showed in each table.
Discussion
In the present study, we evaluated the bone and soft tissue tumors, and tumor-like lesions in a local population consisted of military personnel and their families in a tertiary military hospital. Our results seem to be an indicator for geographic distribution of musculoskeletal tumors which may be cater to an entire country.
There are few comprehensive epidemiological reports to demonstrate the incidence and diagnostic distribution of musculoskeletal system tumors in Turkey. In a large population study of 20-year data, Yuceturk et al. reported a total of 5658 musculoskeletal tumor cases to be aware of the specific rates in Aegean region (6), moreover Dabak et al. published a 25-year data of musculoskeletal tumors including 1925 cases from the central Black sea region (7). In a recent report, Ozturk et al. experienced a total of 3,133 patients with the diagnosis of musculoskeletal tumors from different regions of Turkey in their tertiary care center (8). Among those previous reports, only one presents the data of musculoskeletal oncology experience in military personnel which is carried out in our hospital 26 years ago. In this report, Gür et al. presented their 10-year experience of 420 musculoskeletal tumor patients in a tertiary military hospital (9). Their findings were consistent with the literature regarding the prevalence of bone, soft tissue tumors and metastasis in Turkey. Our study may be considered as the continuation of the Gür et al.'s study regarding the incidence of musculoskeletal tumors in military personnel and families.
There is no study of distribution of musculoskeletal tumors regarding the localization of skeleton in terms of upper and lower extremities yet. In our results, primary soft tissue tumors are most frequently seen in upper extremities than malignant soft tissue tumors, on the contrary malignant primary bone tumors are mostly seen in lower extremities than upper extremities.
Considering the prevalence of tumors, the most common benign soft tissue tumors were reported as lipoma, ganglion and giant cell tumor of tendon sheath, respectively, which was consistent with the literature (6–8). Whereas, the most common malignant soft tissue tumors have been reported as liposarcoma, pleomorphic cell sarcomas (malign fibrous histiocytomas), leiomyosarcomas, and synovial sarcomas, respectively, in a large referral population (6, 10). In our series, most common malignant soft tissue tumor was liposarcoma, then synovial sarcoma took place. Excepting pleomorphic cell sarcomas and leiomyosarcomas, the result showed consistency with the literature.
In similar epidemiological studies all around the world, it is conducted that primary benign bone tumors have higher incidence than malignant ones (11–14). In our study, benign bone tumors accounted for 47% of all our patients in consistency with those reports. Moreover, osteochondroma, simple bone cyst, and chondromas were the most common benign lesions identified in those reports. In a report it is accounted for 21.3% of all tumors, while the percentage of 28.5% among all tumors was reported in another study (12, 14). Similarly, osteochondroma, enchondroma, and simple bone cysts were the most common ones observed in upper extremity in our study, and osteochondroma accounted for 21.6% of all benign bone tumors. There is controversy related to the incidence of aneurysmal bone cyst which was found to be the fourth most common benign tumor in upper extremity. Interestingly, osteoid osteoma followed as the second most common benign bone tumor after osteochondroma, constituting a relatively high percentage of all tumors in the lower extremity. Kitsoulis reported an incidence of osteoid osteoma to represent 11% of all benign bone tumors (15), whereas it was found to be 18% of all benign tumors, predominantly in the lower extremities.
Malignant bone tumors accounted for 10% of all tumors, and 18% among all bone tumors, respectively, in this study. Among the malignant bone tumors, osteosarcoma was the most commonly encountered in the literature (6, 8, 9, 14, 16), however Sevimli reported chondrosarcoma as the most common malignant bone tumor in their locally designed studies (17). Bergovec et al. reported chondrosarcoma to be the second most common of all tumors, with its accounting of 2.9%, as Unni et al. in a study of bone malignancies, reported chondrosarcoma to be the third most common of all bone tumors, at 10.7% (14, 18). In the present study, the most common primary malignant bone tumor was osteosarcoma, with an incidence of 39% of all malignant bone tumors, predominantly in the lower extremity and consistently with the literature. Ewing sarcoma and chondrosarcoma were the second and third most common malignant bone tumors, accounted for 20 and 15%, respectively.
In the present study, the most common localizations of metastasis were found as femur and humerus, predominantly in the lower extremity. Though most common localizations of metastasis have been reported in vertebral column, surgical management has been encountered by neurosurgery clinics of our hospital. On the other hand, the most vertebral column metastasis could be treated conservatively in our clinic which would be the reason of the less common incidence of this region.
Regarding sex, male dominancy has been reported with a ratio of 1.5 for musculoskeletal tumors by Solooki et al.'s (13), whereas Solakoglu and Benzer (19) reported a male dominancy in bone tumors and female dominancy in soft tissue tumors which was supported by Ozturk et al. (8). In the current study, musculoskeletal tumors have been found more common in males than females which could be contributed to the study population of male domination.
This study gives an overview of the surgical experiences of military doctors in musculoskeletal oncology. Beyond a great experience over years in trauma surgery due to war injuries which may considered as the bad fate of the country, musculoskeletal tumor surgery has been a great part as trauma surgery. In the past, a similar study has been reported by our masters which may be determined as preliminary reports of the experience of military doctors in musculoskeletal oncology. However, development of technology in the orthopedic industry and treatment strategies have occurred in the past several years which could attribute us using custom-made implants in the management of necessary situations. Our 3D reconstruction center allowed us to manage some malignant lesions with custom-made implants. It is initially designed and constructed for reconstruction of bone defects in military personnel sustained to war-related injuries and their families, then it is adopted to other situations of dental clinic, neurosurgery and orthopedics including dental defects, cranial defects, and musculoskeletal oncologic reconstructions. On the basis of this, we have performed one custom-made tumor resection prosthesis in a young female with a diagnosis of fibrosarcoma in iliac wing which was not a possible treatment modality in our country. Further studies of this topic is warranted which could shed more light on newer changes in trends of musculoskeletal tumors, enabling creation of better, and newer strategies for diagnosing and treatment.
Furthermore, there are several studies from different regions in Turkey which were also aimed to present the geographical distribution of bone and soft tissue tumors, however the results showed that there was no any regional difference (6, 9, 19). Moreover, our results in terms of distribution and epidemiology showed parallel findings previously reported relevant published data in other developed and underdeveloped countries from all around the world (5, 11–15).
There are some limitations in this study. First this is a retrospective study of prospectively gathered data, and while collecting data we noted a 5% of lost data and wrong diagnosis (especially in tumor-like lesions) due to incomplete medical records. So, we did not comment on the incidence of tumor-like lesions in the study. Second as our clinic is not the referral center for spinal surgery, we assume the incidence of musculoskeletal tumors and metastasis affecting the spine greater than reported in this study. Third, this paper contains only data about surgically treated tumors, however some benign soft tissue and bone tumors, and tumor-like lesions are discovered accidentally and most of which do not need biopsy or surgical management. It is clear that the incidence of such lesions and tumors is much higher than reported, but there is not a method to determine this situation exactly. Last we have not enough data comparing the outcomes of chemotherapy in Ewing sarcoma and other tumors.
Conclusions
In conclusion, though musculoskeletal disorders are rare, the principles of management should be well-known by increasing the awareness to this highly subspecialized field. In our country it is well-established by tertiary military hospital as other several referral centers, however there is still need for highly equipped oncology centers with the growing population of the world.
Statements
Data availability statement
The datasets generated for this study are available on request to the corresponding author.
Ethics statement
The studies involving human participants were reviewed and approved by Gülhane Military Medical Academy Local Ethics Committee (2014–13).
Author contributions
CN and YE substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data, drafting the article or revising it critically for important intellectual content, and final approval of the version to be published.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1.
Lozano CalderoneSARaskinKAHornicekFSchwabJH. What's new in orthopaedic oncology. J Bone Joint Surg Am. (2015) 97:2061–7. 10.2106/JBJS.O.01015
2.
MillerBJRajaniRLeddyLCarmody SoniEEWhiteJRMusculoskeletal Oncology Research Initiative. How much tumor surgery do early-career orthopaedic oncologists per- form?Clin Orthop Relat Res. (2015) 473:695–702. 10.1007/s11999-014-3934-x
3.
LavyCBMkandawireNHarrisonWJ. Orthopaedic training in developing countries. J Bone Joint Surg Br. (2005) 87:10–1. 10.1302/0301-620X.87B1.15713
4.
LeungKSNgaiWKTianW. Orthopaedic training in China: experiences from the promotion of orthopaedic specialist training in China. J Bone Joint Surg Br. (2011) 93:1165–8. 10.1302/0301-620X.93B9.27101
5.
LewinJPuriAQuekRNganRAlcasabasAPWoodDet al. Management of sarcoma in the Asia-Pacific region: resource-stratified guidelines. Lancet Oncol. (2013) 14:e562–70. 10.1016/S1470-2045(13)70475-3
6.
YücetürkGSabahDKeçeciBKaraADYalçinkayaS. Prevalence of bone and soft tissue tumors. Acta Orthop Traumatol Turc. (2011) 45:135–43. 10.3944/AOTT.2011.2504
7.
DabakNÇirakliAGülmanBSelçukMBBarişS. Distribution and evaluation of bone and soft tissue tumors in the middle Black Sea Region. Acta Orthop Traumatol Turc. (2014) 48:17–24. 10.3944/AOTT.2014.3013
8.
ZtürkRArikanSMBulutEKKekeçAFÇelebiFGüngörBS. Distribution and evaluation of bone and soft tissue tumors operated in a tertiary care center. Acta Orthop Traumatol Turc. (2019) 53:189–94. 10.1016/j.aott.2019.03.008
9.
GürEBaşbozkurtMAteşalpASKirdemirVBaydarMLErlerK. 11 years retrospective analysis of bone and soft tissue tumors. Acta Orthop Traumatol Turc. (1993) 27:82–6.
10.
KransdorfMJ. Malignant soft-tissue tumors in a large referral population: distribution of diagnoses by age, sex, and location. AJR Am J Roentgenol. (1995) 164:129–34. 10.2214/ajr.164.1.7998525
11.
BarbosaCSAraujoABMirandaD. Incidence of primary benign and malignant neoplasms and bone pseudotumoral lesions. An epidemiologic analysis of 585 cases diagnosed at the Facultad de Medicina of the Universidad Federal de Minas Gerais. AMB Rev Assoc Med Bras. (1991) 37:187–92.
12.
Baena-OcampoLdCRamirez-PerezELinares-GonzalezLMDelgado-ChavezR. Epidemiology of bone tumors in Mexico City: retrospective clinicopathological study of 566 patients at a referral institution. Ann Diagn Pathol. (2009) 13:16–21. 10.1016/j.anndiagpath.2008.07.005
13.
SolookiSVosoughiARMasoomiV. Epidemiology of musculoskeletal tumors in Shiraz, south of Iran. Indian J Med Paediatr Oncol. (2011) 32:187–91. 10.4103/0971-5851.95138
14.
BergovecMKubatOSmerdeljMSeiwerthSBonevskiAOrlicD. Epidemiology of musculoskeletal tumors in a national referral orthopedic department. A study of 3482 cases. Cancer Epidemiol. (2015) 39:298–302. 10.1016/j.canep.2015.01.015
15.
KitsoulisPMantellosGVlychouM. Osteoid osteoma. Acta Orthop Belg. (2006) 72:119–25. Available online at: http://actaorthopaedica.be/assets/1250/02-Kitsoulis.pdf
16.
CampanacciM. Bone and Soft Tissue Tumors: Clinical Features, Imaging, Pathology and Treatment. 2nd ed. New York, NY: Springer-Verlag (1999).
17.
SevimliR. Distribution and evaluation of primary bone and soft tissue tumors admitted from Malatya province and surrounding provinces. Med Sci. (2017) 6:546–50. 10.5455/medscience.2017.06.8619
18.
UnniKKInwardsCYBridgeJAKindblomLGWoldLE. Tumors of the Bones and Joints. Series 4. Fascicle 2. Silver Spring, MD: ARP Press (2005).
19.
SolakogluDBenzerE. Distribution of bone tumors according to age, sex and tumor site. Acta Oncol Turc. (2005) 38:38–43.
Summary
Keywords
tumor, musculoskeletal, military, experience, benign, malignant
Citation
Neyisci C and Erdem Y (2020) Battle Against Musculoskeletal Tumors: Descriptive Data of Military Hospital Experience. Front. Public Health 8:97. doi: 10.3389/fpubh.2020.00097
Received
08 August 2019
Accepted
10 March 2020
Published
25 March 2020
Volume
8 - 2020
Edited by
Jimmy Thomas Efird, University of Newcastle, Australia
Reviewed by
Kaan Erler, Near East University, Cyprus; Mehmet Ali Deveci, Koç University Hospital, Turkey
Updates
Copyright
© 2020 Neyisci and Erdem.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Cagri Neyisci cagri_neyis@yahoo.com; drcagrineyisci@gmail.com
This article was submitted to Life-Course Epidemiology, a section of the journal Frontiers in Public Health
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.